血管紧张素Ⅱ受体阻滞剂临床应用进展

[1] Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study[J] . The Lancet . 2007 (9571)

[2] Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program[J] . Anique Ducharme,Karl Swedberg,Marc A. Pfeffer,Alain Cohen-Solal,Christopher B. Granger,Aldo P. Maggioni,Eric L. Michelson,John J.V. McMurray,Lars Olsson,Jean L. Rouleau,James B. Young,Bertil Olofsson,Margareta Puu,Salim Yusuf.American Heart Journal . 2006 (1)

[3] Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol[J] . Journal of the American College of Cardiology . 2005 (5)

[4] Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)[J] . Joachim Schrader,Stephan Lüders,Anke Kulschewski,Frank Hammersen,Kerstin Plate,Jürgen Berger,Walter Zidek,Peter Dominiak,Hans Christoph Diener.Stroke . 2005 (6)

[5] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial[J] . Stevo Julius,Sverre E Kjeldsen,Michael Weber,Hans R Brunner,Steffan Ekman,Lennart Hansson,Tsushung Hua,John Laragh,Gordon T McInnes,Lada Mitchell,Francis Plat,Anthony Schork,Beverly Smith,Alberto Zanchetti.The Lancet . 2004 (9426)

[6] The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial[J] . Hans Lithell,Lennart Hansson,Ingmar Skoog,Dag Elmfeldt,Albert Hofman,Bertil Olofsson,Peter Trenkwalder,Alberto Zanchetti.Journal of Hypertension . 2003 (5)

[7] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol[J] . The Lancet . 2002 (9311)

[8] Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II[J] . Bertram Pitt,Philip A Poole-Wilson,Robert Segal,Felipe A Martinez,Kenneth Dickstein,A John Camm,Marvin A Konstam,Günter Riegger,George H Klinger,James Neaton,Divakar Sharma,Balasamy Thiyagarajan.The Lancet . 2000 (9215)

[1] Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study[J] . The Lancet . 2007 (9571)

[2] Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program[J] . Anique Ducharme,Karl Swedberg,Marc A. Pfeffer,Alain Cohen-Solal,Christopher B. Granger,Aldo P. Maggioni,Eric L. Michelson,John J.V. McMurray,Lars Olsson,Jean L. Rouleau,James B. Young,Bertil Olofsson,Margareta Puu,Salim Yusuf.American Heart Journal . 2006 (1)

[3] Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol[J] . Journal of the American College of Cardiology . 2005 (5)

[4] Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES)[J] . Joachim Schrader,Stephan Lüders,Anke Kulschewski,Frank Hammersen,Kerstin Plate,Jürgen Berger,Walter Zidek,Peter Dominiak,Hans Christoph Diener.Stroke . 2005 (6)

[5] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial[J] . Stevo Julius,Sverre E Kjeldsen,Michael Weber,Hans R Brunner,Steffan Ekman,Lennart Hansson,Tsushung Hua,John Laragh,Gordon T McInnes,Lada Mitchell,Francis Plat,Anthony Schork,Beverly Smith,Alberto Zanchetti.The Lancet . 2004 (9426)

[6] The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial[J] . Hans Lithell,Lennart Hansson,Ingmar Skoog,Dag Elmfeldt,Albert Hofman,Bertil Olofsson,Peter Trenkwalder,Alberto Zanchetti.Journal of Hypertension . 2003 (5)

[7] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol[J] . The Lancet . 2002 (9311)

[8] Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II[J] . Bertram Pitt,Philip A Poole-Wilson,Robert Segal,Felipe A Martinez,Kenneth Dickstein,A John Camm,Marvin A Konstam,Günter Riegger,George H Klinger,James Neaton,Divakar Sharma,Balasamy Thiyagarajan.The Lancet . 2000 (9215)